港股異動丨固生堂拉昇漲超10%,去年收入、經調整淨利同比均增長超30%
港股市場醫藥概念股集體走強,其中,昨晚公佈業績的固生堂(2273.HK)盤初一度拉昇漲超10%,報35.6港元。固生堂昨晚公佈業績顯示,2024年收入30.22億元,同比增長30.1%;毛利9.09億元,同比增長29.9%;經調整溢利淨額4.00億元,同比增長31.4%,擬派末期股息每股0.41港元。另外,行業消息面上,光大證券指出,近期醫藥行情整體已顯現見底回暖跡象。近期政策傾斜加老齡化提速,消費醫療復甦箭在弦上。消費醫療的復甦,也契合政策主線、受益於消費力復甦的方向,魚躍醫療、固生堂等可關注。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.